Recent advances in epicutaneous immunotherapy and potential applications in food allergy
Authors:
Open Access
- 27 October 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 4, 1290003
Abstract
Given the potent immunological properties of the skin, epicutaneous immunotherapy (EPIT) emerges as a promising treatment approach for inducing immune tolerance, particularly for food allergies. Targeting the highly immunocompetent, non-vascularized epidermis allows for the application of microgram amounts of allergen while significantly reducing the risk of allergen passage into the bloodstream, thus limiting systemic allergen exposure and distribution. This makes EPIT highly suitable for the treatment of potentially life-threatening allergies such as food allergies. Multiple approaches to EPIT are currently under investigation for the treatment of food allergy, and these include the use of allergen-coated microneedles, application of allergen on the skin pretreated by tape stripping, abrasion or laser-mediated microperforation, or the application of allergen on the intact skin using an occlusive epicutaneous system. To date, the most clinically advanced approach to EPIT is the Viaskin technology platform. Viaskin is an occlusive epicutaneous system (patch) containing dried native allergen extracts, without adjuvants, which relies on frequent application for the progressive passage of small amounts of allergen to the epidermis through occlusion of the intact skin. Numerous preclinical studies of Viaskin have demonstrated that this particular approach to EPIT can induce potent and long-lasting T-regulatory cells with broad homing capabilities, which can exert their suppressive effects in multiple organs and ameliorate immune responses from different routes of allergen exposure. Clinical trials of the Viaskin patch have studied the efficacy and safety for the treatment of life-threatening allergies in younger patients, at an age when allergic diseases start to occur. Moreover, this treatment approach is designed to provide a non-invasive therapy with no restrictions on daily activities. Taken together, the preclinical and clinical data on the use of EPIT support the continued investigation of this therapeutic approach to provide improved treatment options for patients with allergic disorders in the near future. The investigation of immunotherapeutic strategies has increased exponentially since the rapid rise in the prevalence of food allergy at the turn of the century. Although the first report of food allergy immunotherapy for eggs dates back more than a century, only small case reports on the use of oral immunotherapy (OIT) appeared sporadically in the literature until 1998, when Patriarca et al. published the first in a series of reports demonstrating that a protocol of oral therapy could be effective in desensitizing children with immunoglobulin E (IgE)-mediated food allergy (1, 2). Numerous clinical trials proving the efficacy of OIT in desensitizing patients to a variety of food allergens have appeared in the literature. However, while OIT has been the most extensively studied form of food allergy immunotherapy, several drawbacks, such as the high adverse reaction rate (including anaphylaxis), disruption to lifestyle, and loss of protection after discontinuing therapy, have led to the search for more convenient and safer forms of therapy. In 1992, a brief report on the use of rush subcutaneous immunotherapy (SCIT) suggested the benefit of subcutaneous injections of peanut protein, but continued studies from the same group suggested unacceptable adverse side effects (3, 4). More recently, investigators have been evaluating sublingual immunotherapy (SLIT), epicutaneous immunotherapy (EPIT), and intralymphatic immunotherapy and biologics such as omalizumab and dupilumab, alone and in combination with OIT (5). Among these emerging therapeutic options, EPIT is a promising approach that leverages the unique immune properties of the skin to induce a specific immunological response. Although the overall treatment goal of inducing desensitization is common to all forms of allergen immunotherapy (AIT), important differences exist in terms of efficacy, safety, and administration for each treatment modality. Each of these treatment characteristics is impacted by the route of allergen exposure and the underlying mechanism by which desensitization occurs. This review will examine in detail the mechanism, safety, and efficacy of EPIT as shown in clinical and preclinical studies, with a focus on its application in food allergy. The skin is the largest organ of the body and is an incredibly complex, multifunctioning, and self-renewing organ playing multiple physiological roles. The most well-known function of the skin is to provide a physical barrier against mechanical damage, entry of foreign compounds, and ultraviolet light and prevent dehydration by retaining body fluids and moisture. However, the skin is not a simple inert and inflexible barrier. As a constant environmental sensor, the skin is a rather “selectively permeable” environmental interface able to constantly sense and dynamically respond to environmental stimuli. The ability of the skin to act as a multifunctional organ is closely related to its complex lamellar structure, which consists of an outer, non-vascularized epidermis overlying an inner dermis (6). Multiple strata of keratinocytes in the epidermis give the skin its resistance and rigidity, while the dermis mainly contains collagen fibers, which provide a structural framework and give the skin its elasticity and stretch. The human epidermis is composed of several layers of keratinocytes, at various differentiation stages, organized as four layers of proliferating cells, namely, the stratum basale, overlaid by several superficial layers of stratum spinosum and stratum granulosum (SG), which ultimately form the stratum corneum (SC), more commonly known as the “horny layer.” As the outermost layer of the skin, the SC is the first line of defense for the body and is largely responsible for the protective barrier that prevents unwanted materials from entering and excessive loss of water (7). The SC is composed of multiple layers of corneocytes, which are anucleate keratinocytes that have reached the final stage of keratinocyte differentiation. Corneocytes embed keratin filaments within a filaggrin matrix, and the cornified lipid envelope replaces the keratinocyte plasma membrane. Thus, the SC has a two-compartment structural organization in which corneocytes are embedded in a complex lipid matrix, prompting its comparison to a “brick-and-mortar” structure (8). Depending on the body location, corneocytes are stacked in up to 18–20 layers, and corneodesmosomes hold them together and are programed to go through a gradual degradation that enables the desquamation of the outermost layer of corneocytes. In the SG, cell–cell junctions called tight junctions (TJs) seal the keratinocytes together, forming a barrier that acts as a liquid–liquid interface and restricts the movement of molecules within the intercellular space. These TJs act as a “gate” for the passage of water, ions, and solutes through the paracellular pathway and serve to prevent excessive water loss and desiccation (9, 10). With the SC, TJs constitute the second physical barrier of the skin. Aside from acting as a physical barrier, the skin has also evolved into a highly competent immune organ densely populated by diverse and dynamic innate and adaptive immune effector cells that provide a robust first line of defense against exogenous threats, such as toxins and microbial pathogens (11, 12). Skin antigen-presenting cells (APCs), such as Langerhans cells (LCs) located in the epidermis and conventional dendritic cells (cDC1 and cDC2) in the dermis, are dedicated to the elicitation of an adaptive immune response through the capture and processing of antigens and the triggering of antigen-specific T-cell proliferation upon migration to draining lymph nodes and antigen presentation. The human epidermis may also contain CD8+ resident memory T (TRM) cells (a subset of non-circulating memory T lymphocytes that appear following the resolution of skin inflammation) and inflammatory dendritic epidermal cells (IDEC) (a subset of professional APCs that resides at the dermal–epidermal junction of lesional skin during skin inflammatory diseases) (13, 14). The dermis contains several other types of immune cells such as γδ T cells, innate lymphoid cells, CD4+ T cells, neutrophils, macrophages, and mast cells. This mixed population forms a complex and dynamic immune network allowing for the rapid induction of immune responses. As the predominant cell population of the epidermis and being on the front line of defense, keratinocytes play a pivotal and strategic role in this system by acting as immune sentinels. Indeed, keratinocytes express a wide range of pathogen-associated molecular pattern (PAMP) receptors, such as toll-like receptors, allowing them to sense exogenous compounds and distinguish between dangerous pathogens and innocuous molecules or microorganisms (15). Keratinocytes can also sense and react to epidermal injuries by changing morphology and gene expression in response to mechanical insults, sometimes referred to as the “keratinocyte activation” state (16). Keratinocytes then initiate and orchestrate appropriate immune defense responses, such as the recruitment and activation of memory T cells and the activation/maturation of DCs, via the secretion of various proinflammatory cytokines, chemokines, and antimicrobial peptides, also referred to as “alarmins” (12, 17). This unique characteristic recently earned keratinocytes the nickname “cytokinocytes” (18). Sir Edward Jenner established an interest in the skin as an interface between innate and adaptive immunities several centuries ago. Jenner's (19) work provided the very first scientific evidence that the skin can be used to generate an adaptive immune response to a pathogen—in this case, cowpox virus administered on scarified skin. Since this pioneering work, several groups, including ours, have confirmed that skin is a viable route for vaccination against pathogens and cancer and a relevant alternative to intramuscular or subcutaneous injections, provided that the skin barrier is altered by abrasion, microperforation, or tape stripping (20–29). Several comparative non-clinical and clinical studies reported that transcutaneous immunization can be as efficient or even superior to parenteral routes at inducing or reactivating specific T-cell responses (30–33). In line with this unique ability to regulate specific immune responses to topical antigens, the skin likely plays pivotal roles in both allergen sensitization (34) and desensitization (35), depending upon the local inflammatory milieu, the state of the skin barrier, genetic predisposition, and timing of allergen exposure. It is not contradictory, but rather context-dependent, that the skin is capable of orchestrating these two very different immune responses. In terms of the capacity of the skin to promote allergen sensitization, the “dual allergen” hypothesis proposes that sensitization to food allergens may occur when the allergen is first presented to the immune system via an inflamed, eczematous skin, rather than orally, and arises from the observation that allergic individuals often react to their very first oral food allergen exposure, suggesting that prior sensitization had occurred. This hypothesis suggests that sensitization may occur in genetically susceptible individuals [including those with filaggrin mutations (36)] when the disrupted and/or inflamed skin (e.g., atopic eczema) is exposed to low-dose allergen prior to oral exposure, whereas early consumption/exposure to the same allergen leads to oral tolerance (37). Clinical studies have supported this concept showing that allergen-specific T cells express the skin-homing marker cutaneous lymphocyte antigen (CLA) in milk- and peanut-allergic individuals (38, 39). Although this hypothesis conceptually implies that restoring skin barrier functions by enhancing the level of skin hydration should prevent allergen sensitization, this has not been a universal finding (40, 41). In contrast to the immune response of the skin when presented with allergens in the context of inflammation and prior to other routes of exposure, there is now a large amount of evidence that applying allergen on intact and healthy skin areas can progressively lead to immune tolerance, rather than sensitization. The evidence for the capacity of the skin to orchestrate desensitization, in the context of sensitized individuals, and promote tolerance to allergens presented via the epicutaneous route will be examined in detail in the following sections of this review. Surprisingly, the ability of the skin to promote specific immune tolerance has received minimal attention until recently. However, using the skin as a pro-tolerogenic route is a fairly old concept that was established in 1921, when Vallery-Radot and Hangenau (42) revealed that repeated applications of allergens onto the scarified skin reduced systemic allergic symptoms in patients allergic to horses. Only decades later, Senti et al. (43) and Dupont et al. (44) truly exploited this method of repeated antigen application to the skin (now referred to as EPIT) for the treatment of respiratory and food allergies, respectively. In fact, one pivotal role of the skin (and arguably the most important) is to maintain peripheral tolerance and prevent the elicitation of unwarranted immune reactions to harmless environmental agents, such as commensal skin bacteria or even self-antigens (45). Maintenance of tissue homeostasis and immune balance is indeed possible when antigens are sampled by immature and/or semi-mature DCs in the absence or low levels of keratinocyte activation and additional danger signals (17, 46). For instance, uptake of self-antigen by resident DCs leads to a tolerogenic activation process characterized by a slight increase in the expression of major histocompatibility complex (MHC) and costimulatory molecules (including CD80 and CD86), lymph node homing receptor CCR7, tolerogenic transcription factor RelB, and IL-12p40 cytokine, generating semi-mature migratory DCs (47). These “tolerogenic” DCs are unable to provide sufficient costimulatory signals to T cells, leading to T-cell anergy and/or the induction of specific regulatory T cells (Tregs) (Figure 1, left panel). In contrast, a stronger phenotypic maturation occurs when antigens are applied in an inflammatory context or concomitantly with the secretion of high levels of alarmins by keratinocytes, leading to the generation of DCs having acquired an “immunogenic” phenotype (Figure 1, right panel) (17). These activated DCs express high levels of MHC class II (MHC-II) and costimulatory molecules such as CD40 and CD86 and are thereby fully equipped to induce effector T cells rather than Tregs. Those elements perfectly illustrate the “Janus face” of the skin, which can efficiently induce a protective immune response in the case of danger (inflammation, skin barrier disruption, and pathogen invasion) or promote immune tolerance in other situations. Interestingly, there may be anatomical variations in cutaneous immunity. Del Duca et al. (48) illustrated this and analyzed immune cell infiltrates and gene expression profiles of the healthy skin collected from the interscapular upper back, the inner upper arm, the abdomen, and the outer upper thigh of 24 healthy individuals. The upper back contained the highest density of LCs, dermal DCs, and Tregs, suggesting that this skin location may have a particular ability to promote functional tolerance. Figure 1. Epidermal microenvironment predisposes LCs to promote either tolerance or immunity. The skin is composed of three main layers: (i) the SC, composed of multiple layers of corneocytes corresponding to keratinocytes at a final stage of differentiation; (ii) the epidermis, a non-vascularized and rigid layer composed of multiple strata of keratinocytes; and (iii) the dermis that mainly contains collagen fibers. LCs are localized within the epidermis, where they can extend their dendrites to sample antigens having entered the stratum corneum. When taking up antigens under homeostatic conditions (left panel), LCs undergo a tolerogenic activation process characterized by the upregulation of MHC-II, CCR7, RelB, IL-12-p40, and PD-L2 expressions. Upon migration to skin-draining lymph nodes, those tolerogenic LCs preferentially induce Tregs or can promote T-cell anergy. Following injury, infection, or under inflammatory conditions (right panel), keratinocytes secrete high levels of alarmins and other proinflammatory cytokines that drive LC to acquire an immunogenic phenotype, mainly characterized by a strong upregulation of MHC-II and costimulatory molecules (CD40 and CD86) expression. Upon antigen capture and migration to skin-draining lymph nodes, those activated LCs preferentially induce effector T cells such as Th2 cells. As the only professional APCs of the epidermis in homeostatic conditions and being at the forefront of sensing environmental components, LCs are key players in that immune process. LCs are a unique and fascinating population of immune cells derived from hematopoietic precursors sharing features with both macrophages and DCs (49). They are indeed formidable phagocytes that can self-maintain within the epidermis (like macrophages) but also migrate to skin-draining lymph nodes (sdLNs) to present processed antigens to T cells (like conventional DCs) (50, 51). LCs can elongate their dendrites to survey the external environment located just beneath the SC, from which they continuously capture and process self and foreign antigens (52). This unique feature has been remarkably illustrated in a mouse model by Kubo et al. (53), showing that LCs can “send” their dendrites toward the SC by reorganizing TJ structures, thus maintaining TJ barrier integrity during antigen capture. Like other skin DCs, LCs can promote either tolerogenic or immunogenic immune responses depending upon cytokine signals received from keratinocytes. For instance, murine and human LCs can be efficiently stimulated and activated by proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), IL-1β, or thymic stromal lymphopoietin (TSLP), leading to their maturation and switch into an immunogenic profile (54, 55). Of note, the release of these cytokines can be observed following skin barrier disruption in mouse models (e.g., using tape stripping) or in lesional skin areas during topical diseases such as atopic dermatitis, partially explaining why applying antigen on altered and/or inflamed skin can lead to efficient vaccination or sensitization in some cases (56–58). Conversely, data obtained from in vivo mouse models and in vitro clinical samples suggest that LCs migrating from the skin under quiescent conditions can promote a tolerogenic immune response mainly mediated by Tregs in local lymph nodes and skin, resulting in the suppression of allergic/inflammatory responses and restoration of homeostasis (59, 60). Kaplan et al. (61) initially demonstrated the crucial role of LCs in maintaining tolerance to exogenous compounds, showing that contact hypersensitivity to hapten was enhanced in transgenic mice lacking epidermal LCs. Since then, several lines of experimental evidence confirmed that LCs are mainly tasked to maintain peripheral tolerance under steady-state conditions and could even be pre-committed to that function (60, 62, 63). These data further reinforced the concept established by Vallery-Radot and Hangenau and revisited by Senti et al. (43) and Dupont et al. (44), whereby the...Keywords
This publication has 149 references indexed in Scilit:
- Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated microporesVaccine, 2013
- Transcutaneous vaccination via laser microporationJournal of Controlled Release, 2012
- Langerhans cells protect from allergic contact dermatitis in mice by tolerizing CD8+ T cells and activating Foxp3+ regulatory T cellsJournal of Clinical Investigation, 2012
- Langerhans cells are precommitted to immune tolerance inductionProceedings of the National Academy of Sciences, 2011
- Mechanical injury polarizes skin dendritic cells to elicit a TH2 response by inducing cutaneous thymic stromal lymphopoietin expressionJournal of Allergy and Clinical Immunology, 2010
- Langerhans cells as targets for immunotherapy against skin cancerImmunology & Cell Biology, 2010
- External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriersJournal of Experimental Medicine, 2009
- Skin immune sentinels in health and diseaseNature Reviews Immunology, 2009
- Human Keratinocytes Express Functional Toll-Like Receptor 3, 4, 5, and 9Journal of Investigative Dermatology, 2007
- Epicutaneous immunization converts subsequent and established antigen‐specific T helper type 1 (Th1) to Th2‐type responsesImmunology, 2006